Francesca Gay, MD, PhD, discusses the safety and efficacy findings derived from the phase 3 IsKia trial in patients with newly diagnosed multiple myeloma.
Data presented at the 2023 American Society of Hematology (ASH) Annual Meeting and Exposition highlighted improvements in patient-reported outcomes (PROs) with ciltacabtagene autoleucel (cilta-cel) in multiple myeloma (MM).
'This [research] builds on our experience that four-drug combinations with a monoclonal antibody, proteasome inhibitor, immunomodulatory drug, and steroids are superior to three-drug combinations.'
Johnson & Johnson has announced new results from a Phase III study of Carvykti in adults with relapsed lenalidomide-refractory multiple myeloma who have received one to three prior lines of therapy ..
Treatment with CARVYKTI® (ciltacabtagene autoleucel) Resulted in Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Disease-Specific Symptoms in Patients with E... finanzen.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.ch Daily Mail and Mail on Sunday newspapers.